First Cancer Diagnostic Test Based on Rosetta Genomics%27 Proprietary MicroRNA Technology Receives Regulatory Approval

... allow Rosetta Genomics to expedite development and validation of its microRNA-based diagnostic tests ... non-small cell lung cancer. About MicroRNA MicroRNAs (miRNAs) are recently ... strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these...tests using our microRNA technology constitute forward-looking statements for the purposes of the safe...

First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval Tuesday July 22... are diagnosed with Non Small Cell Lung Cancer each year in the United States, with an estimated 60...is designed to differentiate mesothelioma, an asbestos-associated cancer that develops in the pleura, from adenocarcinomas that either arise in the ...

Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify ... Lung Cancer Patients The Project Will Leverage Rosetta Genomics' Proprietary microRNA Extraction ... unnecessary toxicities. The goal of this collaboration is to develop a test that will enable physicians to distinguish between...215,020 new cases of lung cancer in the United States, and approximately 160,000...

...Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV Wednesday August...Will be Screened and Analyzed Using Rosetta Genomics' Proprietary microRNA Technologies REHOVOT, Israel...technologies are based on publicly known human and viral microRNAs in addition to Rosetta Genomics...As a result, these differences may provide for a novel diagnostic strategy for many diseases...

Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics Wednesday June 25, ... biomarkers, to develop a wide range of diagnostic and prognostic tests. This is the company's first collaboration to include a focus on diagnostics for .... I believe that by leveraging the proprietary technologies developed by Rosetta Genomics, this collaboration will be a ...

...(NASDQ: ROSG) announces today that the first molecular test based on Rosetta Genomics' proprietary microRNA technology, developed and validated by Columbia University Medical Center (CUMC), has been approved for clinical ... Laboratory Evaluation Program. CUMC is now finalizing the commercial aspects of this test and will announce its clinical availability to patients nationwide ...

... a microRNA-targeting treatment for hepatitis C in a phase I trial, making the company the first to test such...signatures associated with relapse and progression of breast cancer, as well as the development and validation of...enable us to develop diagnostic products based on our [locked nucleic acid] technology to support ... News , 5/22/2008 ).     Isis Receives $4.6M Payment In Conjunction with ...

  Recs: 0 Re: Anybody left here? Hell, half the world hasn't heard of RNA interference, much less microRNA. Ask your doctor next time you're in. We just arrived WAY early to the party. All early biotech issues languish in the dark long before somebody says "Hey, I wish I'd bought that at $x. Not to say this is a sure thing, but this is no time for impatience. ...

...about stocks: ALNY / ISIS / ROSG The momentum in the microRNA (miRNA) field is continuing to build, as ... test for regulatory approval. The test distinguishes between squamous and non-squamous lung cancer, ... launched the first-ever miRNA based diagnostic test, beating both Rosetta Genomics and... includes two components: the miRNA target and the technology to target it. As a joint venture between ...

... shorts did quite well. Rosetta Genomics, Ltd.,...  develops microRNA-based diagnostic and therapeutic products... ...The ...-based therapeutic products for the treatment of liver cancer and infectious diseases. The company has collaboration and license agreements with... Medical Research Services and Development, Ltd.; U.S. Genomics, Inc.; The Rockefeller University; Max Planck Innovation ...